Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Never in a million years did I think I'd have to limit my chemotherapy.

2.

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

3.

A small rise in cancer was observed following the 1986 Chernobyl accident.

4.

Taking Charge of Your Cancer Journey.

5.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot